Sato Takuma, Seguchi Osamu, Ishibashi-Ueda Hatsue, Yanase Masanobu, Okada Norihiro, Kuroda Kensuke, Hisamatsu Eriko, Sunami Haruki, Watanabe Takuya, Nakajima Seiko, Wada Kyoichi, Hata Hiroki, Fujita Tomoyuki, Fukushima Norihide, Kobayashi Junjiro, Nakatani Takeshi
Department of Transplantation, National Cerebral and Cardiovascular Center.
Circ J. 2016;80(2):395-403. doi: 10.1253/circj.CJ-15-1037. Epub 2015 Dec 22.
Cardiac allograft vasculopathy (CAV) limits long-term success after heart transplant. We assessed the post-transplant risk factors for CAV development.
Patients who underwent heart transplant between May 1999 and December 2013 were included in this study. Patients (n=54) were divided into 2 groups according to the presence or absence of CAV progression after transplant. Coronary angiogram and intravascular ultrasound were conducted within 5-11 weeks after transplant, at 12 months, and annually thereafter. Scheduled endomyocardial biopsies were performed after transplant or whenever acute cellular rejection (ACR) or antibody-mediated rejection was suspected. Twenty-five of 54 patients (46.2%) had CAV progression. ACR ≥ International Society for Heart and Lung Transplantation grade 2 (ACR ≥ 2) and donor age >50 years were significantly associated with CAV development compared with ACR <2 and donor age <50 years. Patients with no history of ACR ≥ 2 and donor age ≤50 years had a significantly low risk of developing CAV compared with the other groups.
Donor age and history of ACR ≥ 2 are independent risk factors for CAV development. Identifying patients at risk of developing CAV is important for appropriate direction of resources and intensity of follow-up.
心脏移植术后的心脏移植血管病变(CAV)限制了长期成功率。我们评估了CAV发生的移植后危险因素。
本研究纳入了1999年5月至2013年12月期间接受心脏移植的患者。根据移植后是否存在CAV进展,将患者(n = 54)分为2组。在移植后5 - 11周、12个月时以及此后每年进行冠状动脉造影和血管内超声检查。移植后或怀疑有急性细胞排斥反应(ACR)或抗体介导的排斥反应时进行定期的心内膜心肌活检。54例患者中有25例(46.2%)出现CAV进展。与ACR <2和供体年龄<50岁相比,ACR≥国际心肺移植学会2级(ACR≥2)和供体年龄>50岁与CAV发生显著相关。与其他组相比,无ACR≥2病史且供体年龄≤50岁的患者发生CAV的风险显著较低。
供体年龄和ACR≥2病史是CAV发生的独立危险因素。识别有发生CAV风险的患者对于合理分配资源和确定随访强度很重要。